Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure
Matthew S Parsons, Anne B Kristensen, Kevin J Selva, Wen Shi Lee, Thakshila Amarasena, Robyn Esterbauer, Adam K Wheatley, Benjamin R Bavinton, Anthony D Kelleher, Andrew E Grulich, Georges Khoury, Jennifer A Juno, Stephen J Kent
EBIOMEDICINE | ELSEVIER | Published : 2021
BACKGROUND: HIV-1 infections occur following viral exposure at anogenital mucosal surfaces in the presence of semen. Semen contains immunosuppressive and pro-inflammatory factors. Semen from HIV-1-infected donors contains anti-HIV-1 antibodies. We assessed if passively infused anti-HIV-1 neutralizing antibody conferred protection from rectal SHIVSF162P3 challenge at semen exposed mucosae. METHODS: We pooled seminal plasma from HIV-1-infected donors. The pool was screened by ELISA for antibodies against HIV-1SF162 gp140. The ability of seminal plasma to inhibit macaque NK cells from responding to direct and antibody-dependent stimulation was assessed. The ability of seminal plasma to inhibit ..View full abstract
Awarded by Australian National Health and Medical Research Council
This work was supported by a grant from the Australian National Health and Medical Research Council (APP1124680) .